If you’ve spent any time looking at job descriptions in the biotech and biopharma industries, or skimming through modern research papers, you have almost certainly seen the term “CHO cells” repeated over and over again.
I remember when I first started applying for biotech roles. CHO cells kept showing up everywhere, especially in pharma manufacturing and process development positions. At that time, my hands-on experience was mostly rooted in bacterial systems like E. coli, and I was somewhat familiar with the potential of human cell lines like iPSCs. But CHO cells? I had no real idea what they were, where they came from, or why they seemed to be the undisputed center of the biomanufacturing universe.
It raised a very simple, logical question for me: If we’re trying to produce human proteins to treat human diseases, why wouldn’t we just use human cells?
Over time, chasing down the answer to that question led me to a much deeper understanding. I didn’t just learn about CHO cells; I learned how the biotech industry actually makes decisions.
This blog breaks down exactly what CHO cells are, why they completely dominate the biopharma landscape, and why human cells are rarely the default choice for large-scale manufacturing.
1. What Are CHO Cells (Without Overcomplicating It)
CHO stands for Chinese Hamster Ovary cells. They are a specific type of mammalian cell line that has, over the last few decades, become the absolute backbone of modern biopharmaceutical production.
At a basic level, CHO cells exist to solve a massive industrial problem by sitting right in the “Goldilocks zone” of biology. On one side of the spectrum, you have bacterial systems. Bacteria are incredibly fast-growing, cheap to feed, and easy to genetically manipulate, but they are severely limited in the types of complex proteins they can produce. On the other side of the spectrum, you have human cells. These are biologically accurate and capable of making perfect human proteins, but they are notoriously finicky, difficult to scale, and expensive to maintain.
CHO cells sit perfectly in between. Today, they are widely used to produce complex biologics, including:
- Monoclonal antibodies (the massive class of therapeutics ending in “-mab”)
- Recombinant therapeutic proteins (like enzymes and hormones)
- Certain complex vaccine components
But the key idea to understand before moving forward is this: CHO cells are not used because they are biologically perfect. They are used because they are extraordinarily reliable at scale.
2. The Real Problem: Producing Human Proteins Is Not Simple
When people first learn about protein production in a classroom, the process sounds deceptively straightforward: you insert a gene of interest into a cell, the cell expresses the protein, and then you purify it.
In reality, making a functional therapeutic is far more complicated. While bacterial systems like E. coli can churn out simple proteins quickly and cheaply, they completely lack the cellular machinery necessary for post-translational modifications (PTMs). The most critical of these is glycosylation—the complex process of attaching specific sugar molecules to a protein after it is built.
And those molecular details matter immensely. For many therapeutic proteins, especially large, complex antibodies, it’s not enough to simply assemble the amino acids. To work properly in the human body, the protein has to be folded correctly into a very specific 3D structure and modified with the right sugar chains. Without these crucial features, the protein might be completely biologically inactive, cleared from the patient’s bloodstream too quickly, or worse, recognized as a foreign threat, triggering a dangerous immune response.
Because bacteria can’t handle these complex modifications, mammalian systems become a strict necessity.
3. Why Not Just Use Human Cells Then?
If mammalian cells are required to make these complex human proteins, the obvious next question is why we don’t default to human cell lines. The answer reveals the distinct gap between academic biology and industrial manufacturing.
Stability and Robustness
Human cell lines tend to be highly sensitive. They are difficult to keep alive under the stressful, high-pressure conditions required for industrial production. CHO cells, on the other hand, have been aggressively adapted over decades to survive and thrive under immense stress. While many human cells are “adherent” (meaning they need a flat surface to attach to and grow), CHO cells have been adapted to thrive in suspension cultures. They can float freely and multiply rapidly in the swirling, mechanically agitated environment of a massive bioreactor, making them incredibly robust workhorses.
Regulatory and Safety Considerations
Using human-derived cells introduces a massive layer of safety concerns, primarily regarding viral contamination. Human cells are naturally susceptible to human viruses (like HIV, Hepatitis, and various respiratory pathogens). If a human cell culture gets contaminated, that pathogen could theoretically be passed on to a patient. Because CHO cells come from hamsters, they lack the specific receptors that human viruses use to invade cells. This natural viral resistance provides an inherent layer of safety. Furthermore, regulatory agencies like the FDA have decades of historical data on CHO cells. That established regulatory confidence significantly reduces the uncertainty and friction during the drug approval process.
Scalability
In the biotech industry, production doesn’t happen in small glass flasks on a lab bench; it happens in giant stainless-steel bioreactors that can hold 10,000 to 20,000 liters of constantly churning liquid. CHO cells are highly optimized for this extreme environment. Decades of intensive process development have made their growth patterns predictable and highly scalable. Human cells, in comparison, frequently struggle to maintain their health, viability, and output at that massive scale.
Consistency and Reproducibility
Pharmaceutical manufacturing depends on one foundational principle: Every single batch must be exactly the same. CHO cells are incredibly amenable to clonal selection. Scientists can screen thousands of CHO cells to find one specific “champion” clone that has stably integrated the target gene and pumps out the exact same high-quality protein, generation after generation. Human cell systems often exhibit higher inherent variability, which introduces unacceptable risks when manufacturing life-saving medicines.
Cost and Process Efficiency
CHO-based manufacturing systems are deeply entrenched. The industry already has billions of dollars invested in existing infrastructure, heavily optimized chemical protocols, specialized feeding media, and established standard operating procedures (SOPs). Switching out this finely tuned engine for a human cell system wouldn’t just be a minor scientific adjustment—it would be a monumental economic and regulatory undertaking that introduces massive operational risk.
4. Why CHO Cells Became the Standard
It’s important to note that CHO cells didn’t become dominant overnight. They gained an early foothold in the biopharma industry back in 1987, when the FDA approved the first recombinant therapeutic protein made in mammalian cells (tPA, a clot-busting drug).
Once that regulatory milestone was crossed, an entire ecosystem began to build around them. CHO cells proved to be incredibly easy to genetically engineer, capable of astronomically high-yield protein production, and highly adaptable to modern, animal-free chemical media. Once the industry successfully validated them at a global scale, the financial and regulatory cost of switching to an entirely new cellular system became prohibitively high.
Success bred more success, and the adoption of CHO cells actively reinforced itself until they became the undisputed gold standard.
5. Are CHO Cells Perfect?
Not at all—and if you want to understand the nuances of the industry, this is important to acknowledge.
CHO cells do not perfectly replicate human biology. Because they are a hamster cell line, their cellular machinery naturally produces glycosylation patterns that are slightly different from those found in native human cells. While usually harmless, these non-human sugar structures can occasionally cause mild immunogenicity (an immune response) in certain patients, or result in proteins that aren’t quite as optimized as they could be.
This reinforces the core reality of industrial biomanufacturing: CHO cells are not chosen because they are biologically identical to humans. They are chosen because they are “good enough” biologically, and undeniably exceptional practically.
6. When Human Cells Are Actually Used
The industry certainly doesn’t ignore human cells; it simply reserves them for when CHO cells truly cannot get the job done. There are several specific scenarios where human-derived systems are the only viable option:
- When ultra-specific human modifications are mandatory: If a therapeutic protein requires exact human glycosylation to function or to avoid a severe immune response, human cells must be used.
- In complex viral production systems: Human cells are highly efficient at producing certain viral vectors.
- In advanced Cell and Gene Therapies: As the industry moves toward cutting-edge modalities, human cells are critical.
In these specialized cases, human-derived systems such as HEK293 cells (Human Embryonic Kidney cells) or iPSC-derived cells (Induced Pluripotent Stem Cells) step into the spotlight. The industry pivots to human cells precisely when the specific biological use-case demands it.
7. Big Picture: It’s Not About “Best,” It’s About “Fit”
One of the most important mental shifts you can make when trying to understand the biotech industry is realizing this: In manufacturing, there is rarely a mathematically “best” system. There is only the system that fits.
Biopharma decisions are driven by three demanding questions:
- What works reliably?
- What scales efficiently and economically?
- What will the FDA and other regulators actually accept?
CHO cells dominate the landscape because they sit perfectly at the complicated intersection of biology, engineering, and regulation. That specific, delicate balance is what makes them so incredibly powerful.
Final Thought
When I first came across CHO cells during my job search, they felt like just another piece of unfamiliar scientific jargon I had to memorize. But understanding why they are used completely changes how you view the industry.
You start to realize that biotechnology is no longer just about pure biology taking place in a petri dish. It is about complex trade-offs, engineering constraints, and highly practical decisions made at a massive, commercial scale.
If you are a student or a professional entering biotech or pharma, grasping this concept gives you a distinct edge. It helps you read research papers with a more critical eye, answer interview questions with genuine confidence, and ultimately think much more like an industry insider. Because once you truly understand why CHO cells dominate the market, you stop asking “Why use this?” and start asking the real engineering question: “What makes this work so well?”
References
- Systematic review and data-driven insights into CHO cell engineering for next-generation antibody production. PubMed Central (PMC). PMC12818826 (2026).
- Factors Affecting the Expression of Recombinant Protein and Improvement Strategies in Chinese Hamster Ovary Cells. Frontiers in Bioengineering and Biotechnology / PubMed Central (PMC). PMC9289362 (2022).
- Industrial Production of Therapeutic Proteins: Cell Lines, Cell Culture, and Purification. PubMed Central (PMC). PMC7121293.
- HEK293 vs CHO Cells for Antibody Expression: Mechanistic Differences, Product Quality, and Strategic Implications. Biointron (2026).
- HEK293 vs CHO: Five Key Application Differences. FDCELL (2025).
Discover more from The Bio-Catalyst
Subscribe to get the latest posts sent to your email.
